A study was performed to investigate the effect of curcumin on the osteogenic differentiation of human periodontal ligament stem cells (hPDLSCs) and its underlying potential mechanism. The Results was that Curcumin at an appropriate concentration had no cytotoxicity and could promote osteogenic differentiation of the hPDLSCs
Full Title of Study: “Alveolar Ridge Augmentation With Curcumin Combined With Xenograft After Piezoelectric Alveolar Ridge Splitting Surgery (A Randomized Controlled Clinical Trial)”
- Study Type: Interventional
- Study Design
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Primary Purpose: Treatment
- Masking: Single (Outcomes Assessor)
- Study Primary Completion Date: March 1, 2024
Patients will be selected from the outpatient clinic of Oral Medicine, Periodontology and Oral diagnosis Department, Faculty of Dentistry, Ain Shams University. The purpose of the study will be explained to all patients and an informed consent will be signed before the conduction of the study .The faculty research ethics committee will review the proposal. The study will be conducted in the form of Patient Intervention Comparative Outcome (PICO) question (Patient "P", Intervention "I", Comparative "C", Outcome "O"). (Stone 2002) "P": Patient in the study will have enough alveolar ridge height ,suffering from missing from 1 to 3 upper maxillary anterior and /or premolar with insufficient alveolar ridge buccolingual (BL) width that interfere with conventional straight forward implant placement. The minimum BL width included in the study will be 4 mm. "I": Ridge splitting with interposition grafting with curcumin and particulate xenograft grafting. "C":Alveolar ridge splitting with interposition grafting with use of particulate xenograft alone without curcumin . "O":Clinical and radiographic outcome.
- Drug: Curcumin
- Curcumin (1,7-bis(4-hydroxy-3-methoxyphenyl)-1,6-heptadiene-3,5-dione) or diferuloylmethane is an important bioactive constituent and hydrophobic polyphenol that isolated from the rhizome of the turmeric plant (Curcuma longa) . Curcumin will be used in combination with xenograft after ridge splitting surgery
Arms, Groups and Cohorts
- Experimental: curcumin combined with particulate xenograft.
- Curcumin will be used in combination with xenograft after ridge splitting surgery Curcumin is widely used in medicine due to medicinal properties, cost-effectiveness, and simple extraction from a turmeric plant that grows in different regions in the world. Recent evidences have shown that curcumin possesses multiple biological activities and pharmacological properties including anti-inflammation , antioxidation , anticancer , antimicrobial , and free radical scavenger effects
- Active Comparator: alveolar ridge splitting with use of particulate xenograft alone.
- xenograft will be used alone after ridge splitting
Clinical Trial Outcome Measures
- clinical outcome
- Time Frame: change from baseline at 6 months
- Assessment the gain in alveolar ridge buccolingual width
- Time Frame: “through study completion, an average of 1 year
- Assessment of the primary implant stability Quotient in the regenerated bone
Participating in This Clinical Trial
- Male and female with age range 25-45 years. – Patient with enough alveolar ridge height, suffering from missing single or multiple maxillary anterior and /or premolar with insufficient alveolar ridge buccolingual (BL) width that interfere with conventional straight forward implant placement. The minimum BL width included in the study will be 4-5 mm to facilitate ridge splitting and expansion. – Systemically free from any diseases as evidenced by Burket's oral medicine health history questionnaire. – Patient available during follow up periods. Exclusion Criteria:
- Smokers. – Pregnant and breast feeding females. – Patient unwilling to comply to oral hygienic instructions. – Patients under any medication or medical condition that affect the bone quality. – Vulnerable groups. (e.g decisions impaired individual).
Gender Eligibility: All
Minimum Age: 25 Years
Maximum Age: 45 Years
Are Healthy Volunteers Accepted: No
- Lead Sponsor
- Ain Shams University
- Provider of Information About this Clinical Study
- Principal Investigator: Yasmine Gamal, Ass.lecturer of oral medicine and periodontology – Ain Shams University
- Overall Official(s)
- Hala A Abuelela, professor, Study Director, faculty of dentistry . Ain Shams University
- Overall Contact(s)
- yasmine G Elbohy, Ass.lecturer, 01283881604, email@example.com
Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.